Sign in

Simon Buczacki

@sibucz.bsky.social
250 followers 268 following 8 posts

Richard Blackwell Pharsalia Professor of Colorectal Surgery | Group Leader, NDS (ORCRB) | Fellow of Linacre | University of Oxford

PostsRepliesMedia
Simon Buczacki @sibucz.bsky.social · 13/11/2025
Another PDOC position in my group to join an ongoing collaborative project between Sanger and BRIC. Funded by Open Targets. my.corehr.com/pls/uoxrecru...
my.corehr.com
Job Details
030
Simon Buczacki @sibucz.bsky.social · 06/10/2025
New CRUK Post-doc position in our group. #mutationalorder #multiomics #cancer. my.corehr.com/pls/uoxrecru...
my.corehr.com
Job Details
046
Simon Buczacki @sibucz.bsky.social · 03/09/2025
t.co/wF4ql4c3V8 We're humbled to have been awarded a CRUK Programme Foundation Award to further progress our work on mutational order in cancer. New post-doctoral positions in our group to be advertised shortly. @ndsurgicalsci.bsky.social @oxfordcancer.bsky.social
t.co
https://www.linkedin.com/posts/cancer-research-uk-science-and-innovation_crukfunded-discoveryresearch-cancerresearch-activity-7368945889794633728-3yLM?utm_source=share&utm_medium=member_desktop&rcm=AC...
152
Simon Buczacki @sibucz.bsky.social · 25/07/2025
Fantastic end to a good week for the lab. Amazing grant news. Paper submitted. Gold LEAF accreditation.
050
Simon Buczacki @sibucz.bsky.social · 14/02/2025
New paper. Why do we try to remove increasingly large numbers of lymph nodes in colon cancer surgery? Here we follow up our BJC 2022 paper with ~370K patients in England and USA. Only 9 LNs are required to stage the cancer. www.nature.com/articles/s41...
nature.com
Lymph node yield as a surrogate marker for tumour biology and prognosis in colon cancer - British Journal of Cancer
British Journal of Cancer - Lymph node yield as a surrogate marker for tumour biology and prognosis in colon cancer
151
Simon Buczacki @sibucz.bsky.social · 27/01/2025
www.cancer.ox.ac.uk/news/oxford-...
cancer.ox.ac.uk
Oxford and GSK launch £50million immuno-prevention programme to advance novel cancer research
Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent ...
0165